Results 161 to 170 of about 932 (190)

Mildronate exerts acute anticonvulsant and antihypnotic effects

Behavioural Pharmacology, 2010
The effects of mildronate [3-(2,2,2-trimethylhydrazinium) propionate], an inhibitor of L-carnitine biosynthesis and an anti-ischaemic drug, were examined in various in-vivo conditions to investigate the neuropharmacological profile after acute administration.
Liga, Zvejniece, Baiba, Svalbe, Marina, Makrecka, Edgars, Liepinsh, Ivars, Kalvinsh, Maija, Dambrova   +5 more
openaire   +2 more sources

The use of the drug mildronate in obstetrics

Journal of obstetrics and women's diseases, 2021
The report contains data on positive influence of mildronatum infusion (10% NaCl) on uterine-placental and fetoplacental circulation in women with chronic placental insufficiency in the third trimester of pregnancy.
N. G. Pavlova, E. I. Krivtsova, N. N. Konstantinova   +2 more
openaire   +1 more source

Mildronate Cardioprotective Action through Carnitine-Lowering Effect

Trends in Cardiovascular Medicine, 2002
Mildronate [3-(2,2,2-trimethylhydrazinium)propionate dihydrate] ameliorates cardiac function during ischemia by modulating myocardial energy metabolism. Biochemical and pharmacological evidence supports the hypothesis that the mechanism of action of mildronate is based on its regulatory effect on carnitine concentration, whereby mildronate treatment ...
Maija, Dambrova, Edgars, Liepinsh, Ivars, Kalvinsh   +2 more
openaire   +2 more sources

Microencapsulation of mildronate in biodegradable and non-biodegradable polymers

Journal of Microencapsulation, 2013
The extremely high hygroscopicity (solubility in water ≥2 g/ml) of the pharmaceutical preparation mildronate defines specific requirements to both packaging material and storage conditions. To overcome the above mentioned inconveniences, microencapsulated form of mildronate was developed using polystyrene (PS) and poly (lactic acid) (PLA) as watertight
Dagnija, Loca, Eduards, Sevostjanovs, Marina, Makrecka, Olga, Zharkova-Malkova, Liga, Berzina-Cimdina, Velta, Tupureina, Marina, Sokolova   +6 more
openaire   +2 more sources

Neuroprotective properties of mildronate, a mitochondria-targeted small molecule

Neuroscience Letters, 2010
Mildronate, a representative of the aza-butyrobetaine class of drugs with proven cardioprotective efficacy, was recently found to prevent dysfunction of complex I in rat liver mitochondria. The present study demonstrates that mildronate also acts as a neuroprotective agent.
Jolanta, Pupure, Sergejs, Isajevs, Elina, Skapare, Juris, Rumaks, Simons, Svirskis, Darja, Svirina, Ivars, Kalvinsh, Vija, Klusa   +7 more
openaire   +2 more sources

EFFECTS OF THE DRUG MILDRONATE

2023
Mildronate (3-(2,2,2-trimethylhydrazine) propionate; THP; MET-88; meldonium, quaterine) is an anti-ischemic drug developed in the Latvian Institute of Organic Synthesis. Mildronate was designed as a promising inhibitor of carnitine biosynthesis aimed to prevent accumulation of cytotoxic intermediate products of fatty acid beta- oxidation in ischemic ...
openaire   +1 more source

Mildronate Ameliorates Kidney Function and Reduces Inflammation in SCD Mice

Blood, 2023
INTRODUCTION:Sickle cell disease (SCD) is a genetic hemoglobin disorder characterized by hemolytic anemia, vaso-occlusive crisis and inflammation that affects organs such as the kidney, liver, brain, spleen, and heart. SCD is driven by a mutation in the β-globin gene that causes sickling of red blood cells (RBCs).
Asrar Ahmad, Clemilson Berto-Junior, Papa Hoyeck, Namita Kumari, Marina Jerebtsova, Sergei Nekhai   +5 more
openaire   +1 more source

Single- and Multiple-dose Pharmacokinetic, Safety and Tolerability Study of Mildronate Injection in Healthy Chinese Subjects Pharmacokinetic of Mildronate Injection

Drug Research, 2015
Mildronate is an agent for cardioprotection and neuroprotection. This study aimed to evaluate the pharmacokinetic (PK) profiles, safety and tolerability of mildronate injection after single escalating doses and multiple doses in healthy Chinese subjects. We performed a randomized, open-label, single- and multiple-dose phase I trial including 3 doses of
Z, Zhao, J, Chen, W, Peng, X, Wang, Z, Chen, H, Tang, Y, Liang, Z, Ma, J, Chen, X, Chen, G, Zhong, M, Huang   +11 more
openaire   +2 more sources